Analystreport

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Stifel Nicolaus from $91.00 to $73.00. They now have a "buy" rating on the stock.

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com